Related content

Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer

By        

Oncology Reports, Vol. 27, Iss. 6, 2012-01 ,pp. : 2066-2072

Spandidos Publications

Access to resources Recommend Favorite

Disease Flare After EGFR Tyrosine Kinase Inhibitor Cessation Predicts Poor Survival in Patients with Non-small Cell Lung Cancer

By Chen Hua-Jun   Yan Hong-Hong   Yang Jin-Ji   Chen Zhi-Hong   Su Jian   Zhang Xu-Chao   Wu Yi-Long  

Pathology & Oncology Research, Vol. 19, Iss. 4, 2013-10 ,pp. : 833-838

Springer Publishing Company

Access to resources Recommend Favorite

Predictors of outcome for EGFR-mutant non-small-cell lung cancer treated with first-line tyrosine kinase inhibitors

By Pilotto Sara   Bria Emilio  

Lung Cancer Management, Vol. 2, Iss. 2, 2013-04 ,pp. : 89-92

Future Medicine

Access to resources Recommend Favorite

EGFR–tyrosine kinase mutation testing methods in non-small-cell lung cancer: new diagnostic guidance is NICE

By Wallace Andrew  

Lung Cancer Management, Vol. 2, Iss. 6, 2013-12 ,pp. : 449-451

Future Medicine

Access to resources Recommend Favorite

Mutational analysis of the insulinlike growth factor 1 receptor tyrosine kinase domain in non-small cell lung cancer patients

By              

Molecular and Clinical Oncology, Vol. 3, Iss. 5, 2015-01 ,pp. : 1073-1079

Science Publishers

Access to resources Recommend Favorite